White Paper

The pros and cons of post-authorisation studies

January 14, 2015

Under European guidelines, all pharmaceutical products receiving or maintaining a marketing authorisation must go through a risk management plan that considers the safety and efficacy of the drug after it has been authorised and made commercially available. Pharmathen considers whether these post-authorisation studies are a burden or an opportunity for industry sustainability.

Download to find out more.